Table 2.
Persistence to osteoporosis medications in the Drug-Specific cohort
| Denosumab | Oral BPs | Parenteral BPs | PTH | SERM | Strontium | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | Naïve | Non-naïve | All | Naïve | Non-naïve | All | Naïve | Non-naïve | All | Naïve | Non-naïve | All | Naïve | Non-naïve | All | Naïve | Non-naïve | |
| Na | 1369 | 177 | 1192 | 161,121 | 44,835 | 116,286 | 81 | 18 | 63 | 91 | 13 | 78 | 1927 | 141 | 1786 | 10,794 | 1206 | 9588 |
| Persistence (%) (95% CI)b | ||||||||||||||||||
| 6 months | 70.1 (67.3–72.7) | 63.8 (56.3–70.4) | 71.3 (68.3–74.0) | 39.7 (39.4–39.9) | 62.4 (61.9–62.8) | 30.6 (30.3–30.8) | 100.0 | 100.0 | 100.0 | 19.8 (12.3–28.7) | 15.4 (2.5–38.8) | 20.6 (12.4–30.2) | 30.2 (28.1–32.3) | 53.2 (44.6–61.0) | 28.3 (26.2–30.4) | 24.6 (23.8–25.4) | 41.0 (38.3–43.8) | 22.4 (21.6–23.3) |
| 12 months | 63.9 (60.8–66.7) | 54.7 (46.8–62.0) | 65.7 (62.4–68.7) | 28.3 (28.1–28.6) | 50.8 (50.3–51.2) | 19.2 (19.0–19.5) | 22.7 (13.5–33.4) | 12.5 (2.1–32.8) | 26.0 (14.9–38.6) | 6.3 (2.4–13.0) | – | 6.9 (2.6–14.1) | 19.4 (17.7–21.3) | 42.2 (33.9–50.2) | 17.6 (15.8–19.4) | 14.1 (13.5–14.8) | 29.7 (27.1–32.3) | 12.1 (11.4–12.8) |
| 18 months | 57.0 (53.8–60.1) | 47.7 (39.7–55.2) | 58.9 (55.4–62.3) | 22.8 (22.6–23.0) | 43.5 (43.0–43.9) | 14.4 (14.2–14.6) | 22.7 (13.5–33.4) | 12.5 (2.1–32.8) | 26.0 (14.9–38.6) | 1.3 (0.1–6.1) | – | 1.4 (0.1–6.5) | 15.2 (13.6–17.0) | 36.7 (28.6–44.7) | 13.5 (11.8–15.2) | 9.7 (9.2–10.3) | 22.8 (20.4–25.3) | 8.1 (7.5–8.6) |
| 24 months | 50.0 (46.3–53.5) | 36.0 (27.4–44.7) | 52.8 (48.9–56.6) | 19.0 (18.8–19.2) | 37.7 (37.2–38.2) | 11.3 (11.1–11.5) | 15.2 (7.5–25.3) | 0.0 | 18.9 (9.3–31.1) | 0.0 | – | – | 12.9 (11.4–14.6) | 32.9 (25.0–41.0) | 11.3 (9.8–12.9) | 6.9 (6.4–7.4) | 16.9 (14.7–19.2) | 5.6 (5.1–6.1) |
| 36 months | 41.5 (36.9–46.1) | 28.0 (16.9–40.2) | 44.0 (38.9–49.0) | 13.9 (13.7–14.1) | 29.3 (28.8–29.8) | 7.6 (7.4–7.8) | 15.2 (7.5–25.3) | 0.0 | 18.9 (9.3–31.1) | 0.0 | – | – | 9.1 (7.6–10.6) | 24.8 (17.2–33.1) | 7.7 (6.4–9.3) | 3.7 (3.3–4.1) | 8.5 (6.8–10.5) | 3.1 (2.7–3.5) |
| 60 months | 16.1 (1.9–42.9) | – | 17.1 (2.0–45.2) | 7.8 (7.5–8.0) | 18.0 (17.4–18.6) | 3.6 (3.4–3.8) | 2.7 (0.2–11.6) | 0.0 | 3.4 (0.3–14.1) | 0.0 | – | – | 4.5 (3.1–6.3) | 22.3 (14.4–31.3) | 3.1 (1.9–4.8) | 0.9 (0.6–1.2) | 2.3 (1.1–4.3) | 0.7 (0.4–1.0) |
Patients could receive multiple drug classes during the observation period. Each patient could therefore have several non-treatment-naïve records but only one treatment-naïve record
BP bisphosphonate, CI confidence interval, PTH parathyroid hormone, SERM selective estrogen receptor modulators
aNumber of records. Patients could contribute multiple records
bPersistence probabilities were estimated using Kaplan–Meier methodology